Abstract
Pixavir marboxil (Yilikang®; 壹立康®) is an oral cap-snatching endonuclease inhibitor being developed by TaiGen Biotechnology for the treatment of influenza virus infections. Pixavir marboxil recently received approval in China for the treatment of uncomplicated influenza A and B in previously healthy adults and adolescents aged ≥ 12 years. This article summarizes the milestones in the development of pixavir marboxil leading to this first approval for uncomplicated influenza A and B infections.
Source:
Link: https://link.springer.com/article/10.1007/s40265-026-02320-2
____
No comments:
Post a Comment